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Osteoarthritis	in	brief	(Part2)	-	Management	
	
Summary	Osteoarthritis	is	a	debilitating	condition	affecting	up	to	20%	of	canine	and	60%	feline	patients.	Whilst	diagnosis	is	fairly	straightforward,	the	aetiology	behind	the	disease	process	and	therefore	the	treatment	strategies	are	not.	Multimodal	management	is	the	mainstay	of	controlling	clinical	signs	and	ensuring	patient	comfort,	however	this	involves	potentially	long-term	pharmacologic	and	dietary	control	and	requires	significant	client	compliance.	Research	into	disease	pathogenesis	and	treatment	strategies	is	ongoing	but	evidence,	especially	relating	to	many	therapies	and	nutritional	supplements	is	currently	lacking.	Genetic	research	continues	as	does	that	into	mesenchymal	stem	cell	therapy	and	cartilage	repair	and	regeneration	but	clinical	“cure”	remains	a	distant	objective.		This	second	article	aims	to	discuss	multimodal	management	of	the	condition	in	more	detail,	including	physical	therapy,	dietary	management,	analgesia	and	surgical	strategies.	It	will	briefly	introduce	the	concept	of	cellular	and	targeted	pharmacologic	treatment	and	will	hopefully	encourage	readers	to	undertake	further	reading	on	these	topics.	
	
Introduction	Whilst	the	first	article	(Companion	Animal,	XXXX	2016)	covered	the	aetiology,	pathophysiology,	and	diagnosis	of	osteoarthritis	(OA),	this	article	aims	to	discuss	the	management	and	therapeutic	options	available	for	treatment	of	the	osteoarthritic	patient.	The	goals	of	OA	therapy	are	to	manage	pain,	maintain	function	and	joint	range	of	motion,	and	maintain	or	restore	normal	activity	(Davidson	&	Kerwin,	2014).	In	general	terms	management	may	be	surgical	or	non-surgical	with	the	latter	involving	a	combination	of	strategies	to	provide	relief	including	analgesia,	weight	management,	exercise	control,	physical	therapy	and	the	use	of	nutraceuticals.	Cellular	therapies	are	also	now	being	developed	and	will	be	mentioned	briefly.		
Weight	management	Obesity	and	increased	body	weight	are	risk	factors	for	developing	OA	(Figure	1).	In	some	studies	there	is	evidence	to	suggest	that	reducing	obesity	in	dogs	with	clinical	signs	of	OA	such	as	lameness	may	lead	to	a	clinical	improvement	(Impellizeri	et	al,	2000;	Budsberg	&	Bartges,	2006)	and	in	human	studies	many	symptoms	are	relieved	through	weight	reduction/obesity	management	alone	(Messier,	2008).	The	incidence	of	obesity	in	client-owned	pets	is	increasing	(German,	2006)	and	achieving	weight	loss	is	challenging,	requiring	both	patience	and	sensitive	client-education	to	encourage	the	feeding	of	calorie-restricted	diets	(German	et	al.,	2007).	In	one	study	in	dogs,	the	loss	of	between	6-8%	of	body	weight	has	been	shown	to	significantly	improve	limb	function	using	objective	(force-plate)	measures	(Marshall	et	al.,	2010)	and	in	a	non-blinded	prospective	study	of	9	overweight	dogs	with	hip	OA,	an	11-18%	reduction	in	bodyweight	correlated	with	a	decreased	severity	of	hind	limb	lameness	(Impellizeri,	2000).	Mlacnik	et	al	(2006)	demonstrated	improved	mobility	and	weight	loss	in	a	prospective	randomized	clinical	trial	of	29	overweight	dogs	involving	caloric	restriction	and	physiotherapy.	Kealy	and	colleagues	reported	that	a	long-term	
25%	restriction	in	food	intake	of	dogs	delayed	the	onset	of	chronic	disease,	including	OA,	and	increased	lifespan,	while	the	prevalence	and	severity	of	OA	was	also	reduced	(Kealy	et	al,	2000,	Kealy	et	al,	2002).	In	a	lifetime	study	on	a	cohort	of	Labrador	retrievers	housed	in	pairs	with	one	fed	ad-libitum	(control)	and	one	fed	at	25%	diet	restriction	(diet-fed)	and	with	similar	distribution	of	hip-laxity	scores	as	ascertained	by	Penn-HIP,	those	diet-fed	had	a	4%	incidence	of	radiographic	hip	osteoarthritis	at	2	years	old,	compared	to	42%	of	the	control	dogs.	By	5	years	old,	13%	of	diet-fed	dogs	had	evidence	of	hip	OA	compared	with	52%	of	control	fed.	The	diet-fed	Labradors	lived	longer	and	at	end-of–life	50%	had	radiographic	evidence	of	hip	osteoarthritis	compared	to	83%	of	control	dogs	(Smith	et	al,	2012).		
Physical	therapy	and	exercise	management	Physical	methods	of	rehabilitation	for	the	OA	patient	include	heat,	cold,	water,	sound,	electricity,	massage	and	exercise	therapy.	Overall,	benefits	relate	to	an	increased	blood	flow	to	the	affected	areas,	reduction	or	resolution	of	inflammation,	preventing	or	minimizing	muscle	atrophy,	preventing	periarticular	contraction	and	the	provision	of	positive	psychologic	effects	for	both	patient	and	owner	(Johnston	et	al,	2008).		The	following	gives	a	brief	overview	of	these	methods	but	the	reader	is	referred	to	other	sources	for	in-depth	discussions	of	physical	therapy	(Johnston	et	al,	2008;	Millis	&	Levine,	2014;	Saunders	et	al,	2005).		Pain	and	stiffness	associated	with	joint	pain	and	osteoarthritis	may	lead	to	lameness	or	reduced	activity,	culminating	in	a	loss	of	muscle	mass	and	limb	strength	(Davidson	&	Kerwin,	2014).	Active	exercise	improves	muscle	strength,	endurance,	cardiovascular	function	and	co-ordination	and	also	reduces	joint	stiffness,	muscle	atrophy	and	bodyweight	(Clark	&	McLaughlin,	2001;	Taylor	et	al,	2004;	Palmoski	&	Brandt,	1984).	Cartilage	loading	during	weight	bearing	may	also	improve	cartilage	metabolism	and	proteoglycan	synthesis	(Millis	&	Levine,	1997;	Palmoski	&	Brandt,	1984).	In	geriatric	patients	with	OA,	controlled,	low-impact	exercise	has	been	shown	to	improve	pain	and	function	scores	(Hudson	&	Hulse,	2004).	A	regular	exercise	program	of	low-impact	activity	including	controlled	lead	walking	and	walking	through	water	can	help	maintain	muscle	strength	whilst	minimising	joint	stress.	Boisterous	impact-activities	and	bursts	of	uncontrolled	activity	should	be	avoided.	In	patients	with	pelvic	limb	disease	sit-to-stand	exercises,	gentle	uphill	walking	or	controlled	stair	climbing	may	be	used	to	improve	pelvic	limb	musculature	(Davidson	&	Kerwin,	2014).	Several	shorter	periods	of	exercise	are	usually	preferred	over	a	single	long	one	(Johnston	et	al,	2008).	Hydrotherapy	reduces	the	amount	of	weight	the	patient	must	support	during	activity,	with	water	depths	above	the	level	of	the	greater	trochanter	reducing	the	weight	borne	by	approximately	50%	(Johnston	et	al,	2008).	Use	of	an	underwater	treadmill	improves	cardiovascular	endurance	and	muscle	strength	whilst	reducing	pain,	improving	balance	and	improving	joint	range	of	motion	(ROM)	(Levine	et	al,	2014)		Passive	stretching	and	passive	ROM	exercises	may	be	utilised	to	improve	joint	function	in	patients	with	OA	(Figure	2).	When	evaluating	the	level	of	passive	ROM	exercises	to	advise	for	a	patient	it	is	important	to	be	aware	that	in	painful	
joints	ROM	is	reduced	and,	if	the	pain	can	be	controlled,	ROM	is	likely	to	improve.	In	cases	where	joint	stiffness	is	evident,	pain	is	often	encountered	towards	the	end	of	normal	ROM.	If	both	joint	stiffness	and	pain	are	present	it	is	useful	to	assess	which	factor	is	dominant	and	to	aim	to	prioritise	treatment	of	that	(Saunders	et	al,	2005).	ROM	exercises	should	always	be	performed	within	a	patient’s	comfort	zone;	excessive	manipulation	may	lead	to	reflex	inhibition,	reduced	limb	use,	tissue	fibrosis	and	a	delay	in	return	to	normal	function	(Johnston	et	al,	2008).	Passive	ROM	exercises	may	be	combined	with	the	use	of	massage	and	heat	therapy	to	provide	increased	levels	of	comfort	during	the	rehabilitation	periods,	and	analgesics	are	often	used	to	improve	patient	comfort	(Tanger	1984).	Stretch	and	balance	exercises	that	focus	on	weight	shifting	help	with	overall	balance	and	proprioception	(Davidson	&	Kerwin,	2014).		Local	hypothermia	can	be	useful	to	treat	patients	with	acute	inflammation.	Application	of	cold	packs	promotes	vasoconstriction	and	skeletal	muscle	contraction	and	reduces	nerve	conduction,	in	turn	reducing	oedema,	improving	venous	return	and	promoting	mild	analgesia.	Following	the	resolution	of	acute	inflammation	and	in	more	chronic	cases	of	OA,	moist	heat	may	be	used,	again	often	benefitting	the	patient	prior	to	passive	and	active	exercise	therapy.	An	increase	in	local	blood	flow	through	local	vasodilatation	and	increased	absorption	of	extravasated	fluids	helps	improve	local	nutrient	delivery	to	the	tissues	and	the	heat	will	also	increase	compliance	of	joint	capsule,	tendons,	and	scar	tissue	reducing	joint	stiffness	and	contributing	to	pain	relief	(Johnston	et	al,	2008).		Laser	therapy,	therapeutic	ultrasound,	transcutaneous	electrical	nerve	stimulation	and	extracorporeal	shockwave	therapy	have	been	evaluated	as	ancillary	treatments	although	the	current	clinical	evidence	for	their	use	in	veterinary	medicine	is	limited.	Readers	are	referred	to	more	specialised	texts	such	as	Millis	&	Levine	(2014)	for	further	information.		
Pain	management	The	majority	of	treatment	of	OA	is	directed	towards	palliating	the	joint	pain	associated	with	the	disease.	It	must	be	remembered	that	signs	of	OA	are	not	consistent	and	there	is	no	single	solution	that	can	be	recommended	in	all	cases.	Lameness,	pain	and	clinical	signs	may	be	severe	in	the	light	of	minimal	radiographic	change	and	vice	versa.	The	severity	of	the	signs	will	also	depend	on	the	amount	of	stress	(use)	the	tissues	both	within	and	around	the	joint	are	exposed	to.	Acute	and	chronic	pain	may	be	present	simultaneously,	necessitating	a	multimodal	pharmacologic	and	non-pharmacologic	approach	(Johnston	et	al,	2008).		Non-steroidal	anti-inflammatory	drugs	Non-steroidal	anti-inflammatory	drugs	(NSAIDs)	with	their	analgesic,	anti-inflammatory	and	anti-pyretic	effects	are	the	most	frequently	prescribed	medication	to	treat	OA.	NSAIDs	have	been	shown	to	be	clinically	effective	to	treat	OA	pain	in	a	number	of	studies	(Innes	et	al,	2010;	Mansa,	2007;	Sanderson	et	al,	2009;	Payne-Johnson	et	al,	2015)	and	a	systematic	review	published	in	2007	found	a	high	level	of	comfort	for	the	use	of	meloxicam	as	clinically	efficacious	for	
treatment	of	OA	in	dogs	(Aragon	et	al,	2007).	In	general,	although	there	is	not	major	evidence	that	any	one	NSAID	is	clinically	superior	to	another	it	is	likely	that	in	specific	individuals,	one	NSAID	may	work	better	than	another	(Johnston,	2008).	In	a	clinical	setting,	it	may	be	prudent	to	alter	the	NSAID	prescribed	if	one	does	not	seem	to	be	achieving	the	desired	outcome,	rather	than	changing	the	entire	analgesic	plan	(KuKanich,	2012).		When	switching	from	one	NSAID	to	another	a	washout	period	is	recommended	in	order	to	avoid	the	possibility	of	adverse	effects.	These	periods	are	arbitrarily	based	on	the	half-life	of	the	drug,	and	presume	that	the	majority	of	a	drug	dose	will	have	been	eliminated	within	4-5	half	lives.	For	most	NSAIDs,	plasma	half-lives	are	between	1-24	hours,	although	in	the	case	of	mavacoxib	is	much	longer,	extending	to	39	days.		Conservative	washout	periods	for	NSAIDs	(with	the	exception	of	aspirin	and	mavacoxib)	are	5-7	days	(Lascelles	et	al,	2005;	Ryan	et	al,	2007).		NSAIDs	work	through	inhibition	of	the	cyclo-oxygenase	(COX)	pathway;	the	key	enzyme	in	the	formation	of	prostaglandins	from	arachidonic	acid.	Prostaglandin	E2	(PGE2)	has	a	number	of	roles	in	enhancing	the	development	of	OA	including	lowering	the	nociceptive	threshold,	promotion	of	synovitis,	enhanced	formation	of	matrix	metalloproteinases	(MMPs)	that	stimulate	cartilage	degradation	and	reduce	chondrocyte	activity,	thereby	preventing	extracellular	matrix	synthesis	and	repair.	In	addition	to	this,	COX	inhibition	within	the	central	nervous	system	reduces	the	arachidonic	acid	catalysed	wind-up	of	NMDA	receptors,	reducing	central	sensitisation	and	chronic	pain	(see	previous	article).		NSAIDs	available	for	use	in	the	UK	and	their	recommended	dose	rates	are	listed	in	Table	1.		Other	analgesics	Due	to	the	complex	pain	mechanisms	present	in	OA,	a	combination	of	drug	therapies	may	be	recommended	in	cases	where	NSAIDs	combined	with	physical	therapy	do	not	adequately	control	clinical	signs.	Whilst	there	are	a	number	of	drugs	that	may	be	combined	with	NSAIDs,	clinical	efficacy	of	them	all	has	not	necessarily	been	proven	and	there	are	only	a	few	studies	that	support	their	veterinary	clinical	use.	If	used,	these	drugs	are	prescribed	off-licence	and	owner	consent	must	be	sought.		Amantadine	is	an	N-methyl-D-aspartate	(NMDA)	receptor	antagonist	and	acts	to	control	central	sensitisation	and	neuropathic/chronic	inflammatory	pain.	In	a	single	study,	Lascelles	et	al	(2008)	reported	the	use	of	amantadine	in	a	multimodal	analgesic	regimen	to	alleviate	refractory	OA	pain	in	dogs.	31	dogs	with	ongoing	pelvic	limb	lameness	despite	NSAID	therapy	were	included	in	a	blinded,	randomized,	placebo	controlled	trial.	Over	the	42-day	study	period	dogs	receiving	amantadine	were	significantly	more	active	and	the	conclusion	was	that	amantadine	may	be	a	useful	clinical	adjunct	therapy	for	the	clinical	management	of	canine	OA	pain.	There	are	two	small	reports	of	some	clinical	benefit	in	both	dogs	(Madden,	2014)	and	cats	(Siao,	2011).	Dose	rate:	dogs	3-5	mg/kg,	p.o.,	q.	24	hours;	cats	1-4	mg/kg	
	Amitryptyline	is	a	tricyclic	antidepressant	used	to	treat	chronic	and	neuropathic	pain	in	humans.	The	drug	inhibits	neuronal	reuptake	of	serotonin	and	noradrenaline,	increasing	the	activity	of	descending	inhibitory	pathways	that	modulate	afferent	nociceptive	input	(Johnston,	2008).	There	are	no	published	clinical	trials	on	the	clinical	use	of	the	drug	in	veterinary	medicine	although	pharmacokinetic	data	has	been	obtained	in	greyhound	dogs	(Norkus,	2015).		Codeine	is	a	pro-drug	that	is	metabolized	into	morphine	and	codeine-6-glucuronide.	It	is	a	schedule	II	drug	(schedule	III	in	combination	with	paracetamol).	Although	there	are	no	published	data	regarding	the	efficacy	of	its	use	in	clinical	OA	it	is	often	used	in	conjunction	with	NSAIDs	for	multimodal	analgesia	and	has	been	used	as	rescue	analgesia	in	a	clinical	trial	of	canine	OA	with	no	adverse	effects	(Innes	et	al,	2003).	Doses	of	0.5-2	mg/kg,	p.o.,	q.	12	hours	in	both	dogs	and	cats.		Corticosteroids	given	either	orally	or	intra-articularly	are	a	controversial	treatment	for	OA	and	they	should	never	be	used	in	combination	with	NSAIDs.	Intra-articular	therapy	may	provide	temporary	remission	of	clinical	signs,	and	is	most	commonly	used	in	patients	with	severe	end-stage	OA	signs	that	are	refractory	to	other	treatments	(Henrotin	et	al,	2005)	but	in	some	cases	chondromalacia	may	develop	and	lead	to	a	worsening	of	the	disease	process	(Murphy	et	al,	2000).	Use	should	be	restricted	to	approximately	3-4	doses	intra-articularly	per	year	to	avoid	the	possible	development	of	these	cartilage-damaging	effects	(Innes,	2012).	If	septic	arthropathy	is	present	corticosteroid,	treatment	is	contraindicated.		The	use	of	intra-articular	hyaluronan	in	combination	with	methylprednisolone	has	recently	been	compared	with	intra-articular	autologous	conditioned	plasma	to	treat	elbow	arthritis	in	dogs	(Franklin	&	Cook,	2013).	Each	treated	group	significantly	improved	with	regard	to	lameness,	pain	and	activity	scores	on	client-based	assessment	although	neither	treatment	proved	to	be	superior.		Gabapentin	is	a	gamma-aminobutyric	acid	(GABA)	analogue.		Although	the	exact	mechanism	of	action	is	unknown	the	effects	of	gabapentin	seem	to	occur	through	blockade	of	voltage-activated	calcium	channels	and	interactions	with	NMDA	receptors	that	are	responsible	for	wind-up	in	the	central	nervous	system	(Sills,	2006).	Gabapentin	is	widely	used	in	human	patients	to	relieve	neuropathic	pain	although,	again,	peer-reviewed	evidence	of	efficacy	in	dogs	does	not	exist.	A	recent	case	series	of	three	cats	with	musculoskeletal	disease	and	head	trauma	reports	a	potential	benefit	of	long-term	treatment	with	gabapentin	in	controlling	chronic	pain	(Lorenz	et	al,	2013).		Dose	of	10mg/kg,	p.o.,	q.	8	hours	in	dogs,	and	5	mg/kg	in	cats.		Paracetamol	is	a	centrally	acting	analgesic	medication	with	widespread	use	in	human	patients	with	osteoarthritis.	The	mechanism	of	action	is	not	known	but	some	interaction	with	serotonin	receptors	and	opiate	pathways	may	be	involved.	Paracetamol	cannot	be	used	in	cats	because	they	lack	the	glucuronyl	transferase	enzyme	required	for	drug	metabolism.	In	dogs	a	dose	of	10-15	mg/kg,	q.	8-12	
hours	is	recommended,	however	the	only	licensed	form	of	this	drug	in	the	UK	is	in	combination	with	codeine	as	Pardale-V®	and	this	is	only	licensed	for	5	consecutive	days.	The	codeine	in	this	preparation	does	not	survive	first	pass	metabolism	so	does	not	appear	to	add	to	the	analgesic	effects	of	the	drug.		Tramadol	is	an	opioid-like	analgesic	that	is	metabolised	to	a	number	of	different	active	compounds,	some	acting	at	opioid	receptor	sites	with	others	modulating	noradrenaline	and	serotonin	receptor	uptake.	A	combination	of	tramadol	with	NSAID	or	paracetamol	has	been	reported	to	be	effective	at	treating	OA	pain	in	people	(Johnston	et	al,	2008)	and	in	one	clinical	trial,	tramadol	proved	more	effective	than	placebo	in	treating	chronic	pain	associated	with	OA	(Malek	et	al,	2012).	Doses	of	2-5	mg/kg,	p.o.,	q.	8	hours.		
Nutritional	supplementation	and	additional	therapeutic	agents	Nutraceuticals	or	dietary	supplements	are	widely	advertised	as	providing	clinical	benefit	to	canine	and	feline	patients	with	OA,	however	evidence	is	limited.	Due	to	the	potential	adverse	side	effects	of	non-steroidal	anti-inflammatories,	and	the	cartilage	degradation	effects	of	intra-articular	steroid	treatment,	ideal	management	of	OA	should	focus	on	prevention	of	the	disease	and	administration	of	safe	long-term	solutions	to	the	problem.	It	has	been	suggested	this	prevention	and	long-term	safe	strategy	may	be	available	in	the	form	of	nutrition	or	dietary	supplements	(Comblain	et	al,	2016).		Chondroitin	Sulphate	and	Glucosamine	McCarthy	et	al	(2007)	demonstrated	that	supplementation	with	chondroitin	sulphate	and	glucosamine	improved	pain	scores	in	dogs	compared	to	carprofen,	although	the	onset	of	effect	was	delayed	in	comparison.	Two	other	canine	studies	demonstrated	significant	improvements	in	pain	compared	to	placebo	in	dogs	with	OA	treated	with	these	supplements	(D’Altilio,	2007;	Gupta,	2012).	In	contrast,	Moreau	et	al	(2003)	identified	no	such	benefit	of	the	nutraceutical	with	subjective	and	objective	measures	of	improvement	only	occurring	in	NSAID-treated	dogs.		Polyunsaturated	fatty	acids	Several	in	vivo	studies	have	evaluated	the	efficacy	of	omega-3	fatty	acids	in	dogs	with	documented	OA,	with	subjective	improvements	in	lameness,	ability	to	rise	from	rest,	and	ability	to	walk,	as	well	as	increases	in	peak	force	seen	in	the	cases	given	dietary	supplements	(Roush,	2010;	Fritsch	et	al,	2010).	In	other	studies,	fish-oil	supplementation	improved	peak	vertical	force	and	owner	quality	of	life	assessments	but	had	no	documented	effect	on	pain	relief	at	the	end	of	the	study	compared	to	placebo	(Hielm-Bjorkman	et	al,	2012).	Administration	of	fish	oil	has	been	shown	to	reduce	inflammatory	markers	such	as	arachidonic	acid,	IL-1,	IL-6	and	PGE2,	which	may	give	reason	for	their	clinical	effects	(LeBlanc	et	al,	2008).		Undenatured	type	II	collagen,	avocado-soyabean	unsaponifiables	and	green-lipped	muscle	have	all	been	evaluated	with	some	studies	showing	positive	effects	on	OA	although	more	evidence	for	their	use	is	required	(Comblain	et	al,	2016,	Rialland	et	al,	2013,	Vendeweerd	et	al,	2012).	
	A	systematic	review	of	the	efficacy	of	nutraceuticals	to	alleviate	clinical	signs	of	OA	in	horses,	dogs	and	cats	found	few	rigorous	randomised,	controlled	clinical	trials,	concluding	that	evidence	for	their	efficacy	was	poor	except	for	diets	supplemented	in	omega-3	fatty	acids	in	dogs	(Vandeweerd	et	al,	2012).		Comblain	et	al’s	(2016)	more	recent	review	concluded	that	whilst	NSAIDs	remain	the	mainstay	of	pharmacologic	therapy	in	cases	of	OA,	dietary	supplements	may	offer	additional	disease-modification,	including	anti-inflammatory	and	chondroprotective	effects,	without	the	recognised	side	effects	of	long-term	pharmacological	treatment.	Whilst	they	conclude	that	nutraceuticals	have	the	potential	to	provide	alternative	means	of	preventing	and	managing	OA	in	dogs,	they	do	highlight	poor	oral	bioavailability	of	many	supplements	and	specify	that	formulations	must	be	altered	in	order	to	improve	this.		Aragon	et	al	(2007)	reviewed	clinical	trials	of	treatments	for	OA	in	dogs	comparing	pharmacologic	and	nutraceutical	agents	and	identified	high	evidence	for	the	use	of	meloxicam	as	a	clinically	efficacious	treatment	of	OA	in	dogs.	Moderate	levels	of	evidence	were	available	for	the	use	of	carprofen,	etodolac,	pentosan	polysulphate,	green	lipped	muscle	P54FP,	polysulphated	glycosaminoglycans	and	a	combination	of	chondroitin	sulphate,	glucosamine	hydrochloride	and	manganese	ascorbate.	Very	poor	evidence	existed	for	the	use	of	hyaluronan	although	human	studies	do	suggest	reduction	in	clinical	signs	and	improvements	in	mobility	(Kuroki	et	al,	2002).		Autologous	platelet	therapy	The	intra-articular	injection	of	autologous	platelets	is	a	potentially	promising	new	therapy	for	OA	in	dogs.	Platelets	contain	growth	factors	that	have	been	shown	to	enhance	regenerative	processes	in	osteoarthritic	joints.	Intra-articular	autologous	platelet	therapy	has	been	documented	to	provide	subjective	improvements	in	human	patients	with	OA	and	significant	improvements	in	lameness,	pain	scores	and	peak	vertical	force	in	a	randomised,	controlled	clinical	trial	in	dogs	with	single	joints	affected	by	OA	have	also	been	documented	(Fahie	et	al,	2013).		Mesenchymal	stem	cells	Stem	cells	are	gaining	increasing	popularity	for	use	in	regenerative	techniques.	Stem	cells	are	undifferentiated	cells	with	the	ability	to	divide	indefinitely	without	losing	their	properties	and	will	eventually	develop	to	produce	specialised	cell	lines.	In	equine	medicine	there	are	a	number	of	reports	advocating	the	use	of	stem	cells	for	ligament	and	tendon	injuries	with	no	adverse	systemic	effects	and	minimal	local	tissue	reaction.		A	couple	of	canine	studies	have	identified	improved	orthopaedic	examination	scores	in	dogs	being	treated	with	intra-articular	mesenchymal	stem	cells	for	OA	(Black	et	al,	2007).		Grapiprant	A	more-targeted	approach	than	the	use	of	NSAIDs	for	treating	OA	would	involve	blockage	of	only	the	part	of	the	prostaglandin	pathway	involved	in	pain	and	inflammation	without	altering	the	protective	mechanisms	of	that	pathway.	
Prostaglandin	E2	is	the	most	abundant	prostaglandin	in	synovia	and	is	pivotal	in	the	development	of	joint	inflammation	and	pain	(Clark	et	al,	2008).	Grapiprant	is	a	new	analgesic	and	anti-inflammatory	drug	that	is	a	highly	potent	and	selective	antagonist	of	the	PGE2	EP4	receptor	in	rodents,	humans	and	dogs.	(Nakao	et	al,	2007).	FDA	approval	has	been	granted	for	the	drug	for	use	in	the	treatment	of	the	pain	and	inflammation	linked	to	OA	and	it	will	be	available	in	the	US	in	Autumn	2016.		Anti-Nerve	Growth	Factor	Antibody	Nerve	growth	factor	(NGF)	is	required	in	the	adolescent	nervous	system	for	development	and	maintenance	of	sensory	and	sympathetic	neurons.	In	adults,	the	growth	factor	has	been	identified	as	pro-nociceptive	with	modulatory	effects	on	the	tyrosine-kinase	receptor	and	is	involved	in	the	sensation	of	pain	including	that	of	OA	(Lascelles	et	al,	2015).	In	canine	studies,	anti-NGF	antibodies	have	been	demonstrated	to	alleviate	pain	in	dogs	with	OA	for	up	to	four	weeks	(Lascelles	et	al,	2015).	Whilst	numbers	in	these	trials	are	low	(35	dogs	in	total)	and	adequate	information	regarding	side	effects	and	long-term	effects	are	lacking,	this	may	be	a	further	useful	adjunct	to	the	management	of	OA	in	the	canine	patient.		Further	detailed	information	on	cellular	therapies	and	targeted	pharmacologic	approaches	to	canine	joint	treatment	can	be	found	in	Perry	(2016a	&	b).		
Surgical	Management	The	goals	of	surgical	treatment	of	OA	are	pain	relief,	amelioration	or	removal	of	pathologic	changes	associated	with	OA	and	maintenance	of	maximal	joint	function	(Cook	&	Payne,	1997).	Whilst	salvage	surgeries	to	treat	OA	may	be	performed,	prevention	is	better	than	cure,	and	correction	of	those	conditions	known	to	cause	OA	is	important	to	reduce	or	slow	the	development	of	the	disease	(Box	1).		Reported	surgical	options	for	treatment	include	synovectomy,	cartilage	grafting	and	osteotomies,	whilst	salvage	procedures	include	excision	arthroplasty,	arthrodesis	and	joint	replacement	(Cook	&	Payne,	1997).	The	procedure	chosen	will	depend	on	the	joint	affected	and	the	disease	process	present;	end-stage	joint	disease	may	require	a	salvage	procedure,	whilst	osteochondral	flap	excision	and	debridement	of	the	underlying	subchondral	bone	bed	from	the	humeral	head	will	manage	discomfort	and	reduce	OA	development	in	the	shoulder	joint	(Martinez,	1997).		Arthroscopic	evaluation	and	treatment	is	a	minimally	invasive	method	of	quantifying	OA	change	and	identifying	the	severity	of	cartilage	damage	(article	1).	Debridement	of	damaged	cartilage,	joint	lavage,	synovectomy	and	releasing	procedures	are	all	performed	arthroscopically	in	human	medicine	to	treat	the	OA-affected	joint	(Cook	&	Payne,	1997)	and	cartilage	resurfacing	using	grafts	has	been	undertaken	in	veterinary	patients	to	treat	osteochondral	lesions	(Cook	et	al,	2008;	Fitzpatrick	et	al,	2010	&	2012a).	Sliding	humeral	osteotomy	and	unicompartmental	cartilage	resurfacing	are	options	available	to	treat	medial	compartmental	disease	of	the	elbow	joint,	where	previously	total	elbow	
replacement	may	have	been	necessary	(Fitzpatrick	et	al,	2015;	Franklin	et	al,	2014).		Surgical	salvage	includes	treatments	such	as	excisional	arthroplasty,	total	joint	replacement	and	amputation.	Whilst	total	hip	replacement	is	commonplace	in	small	animal	practice,	elbow	replacements	are	less	so,	most	likely	due	to	the	high	complication	rates	associated	with	replacement	of	the	complex	elbow	joint.	Excision	arthroplasty	is	a	feasible	option	for	the	coxofemoral	joint	and	digits,	whilst	it	is	a	poor	option	for	functional	outcome	in	the	shoulder.	Arthrodesis	is	an	option	to	provide	good	functional	outcome	in	low-motion	joints	such	as	the	carpus	and	tarsus.	In	higher	motion	joints	results	may	be	less	satisfactory	although	stifle	arthrodesis	and	shoulder	arthrodesis	have	been	reported	with	reasonably	acceptable	outcomes	(Cofone	et	al,	1992;	Fitzpatrick	et	al	2012b).		
Conclusion	OA	is	a	condition	that	affects	large	numbers	of	dogs	and	cats.	Whilst	current	strategies	often	focus	on	the	management	and	treatment	of	OA,	our	focus	for	the	future	should	be	on	disease	prevention	and	disease	modification.	Appropriate	and	early	management	of	primary	orthopaedic	disease,	client	education	and	continuing	research	into	disease-modifying	agents	are	a	priority,	as	is	further	research	and	development	into	ways	to	address	the	condition	in	order	to	improve	quality	of	life	and	avoid	the	necessity	for	salvage	procedures.		 	
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Congenital	conditions	 Acquired	conditions	Osteochondritis	dissecans	(OCD)	 Cranial	cruciate	ligament	disease	Canine	developmental	elbow	disease	Fragmented	medial	coronoid	process	Elbow	OCD	Ununited	anconeal	process	
Joint	Trauma	Articular	fractures	Joint	luxation	Ligamentous	injury	Canine	hip	dysplasia	 	Canine	patella	luxation	 		Box	1:	Congenital	and	acquired	conditions	leading	to	the	development	of	osteoarthritis	(adapted	from	Martinez,	1997	and	Martinez	&	Coronado,	1997)	
 
 
Table	1:	NSAIDs	licensed	for	use	in	the	UK.	The	dosage	is	that	for	patients	with	pain	and	inflammation	associated	with	osteoarthritis	(Data	from	the	VMD	website,	August	2016	and	BSAVA	Formulary,	8th	ed)	
Drug	 Dosage	(UK	licensed)	
	
Indications	 Mechanism	of	action	Carprofen	 Oral	and	injectable	4	mg/kg	once	daily	or	2	mg/kg	twice	daily	for	7	days	reducing	to	2	mg/kg	once	daily	subject	to	clinical	response	
Control	of	postoperative	pain	and	inflammation	following	surgery	and	reduction	of	chronic	inflammation,	e.g.	degenerative	joint	disease,	osteoarthritis.	In	cats	carprofen	is	only	licensed	as	a	single	perioperative	dose	for	the	control	of	postoperative	pain.		
Inhibition	of	COX	enzyme;	in	vitro	selective	against	COX-2	
Cimicoxib	 2	mg/kg	orally	once	daily	 For	the	relief	of	pain	and	inflammation	associated	with	OA	in	dogs	and	the	control	of	peri-operative	pain	in	soft	tissue	and	orthopaedic	surgeries	in	dogs	
A	coxib	class	drug	that	selectively	inhibits	COX-2,	with	a	significant	sparing	effect	on	COX-1	enzyme	synthesis	Firocoxib	 5	mg/kg	orally	once	daily	 For	the	relief	of	pain	and	inflammation	associated	with	OA	in	dogs	and	the	control	of	postoperative	pain	in	soft	tissue	and	orthopaedic	surgeries	in	dogs	
Inhibition	of	COX	activity;	in	vitro	studies	show	high	selectivity	for	COX-2	in	canine	blood	Ketoprofen	 Dogs	-	2	mg/kg	s.c.,	i.m.,	i.v.	once	daily,	may	be	repeated	for	up	to	3	consecutive	days;	0.25	mg/kg	orally	once	daily	for	up	to	30	days	in	total;	1	mg/kg	orally	once	daily	for	up	to	5	days.			Cats	-	2	mg/kg	s.c.	once	daily,	may	be	repeated	for	up	to	3	consecutive	days;	1	mg/kg	orally,	once	daily	for	up	to	5	days.			Oral	dosing	for	4	days	may	follow	a	single	injection	of	ketoprofen	on	day	1	
Relief	of	acute	pain	from	musculoskeletal	disorders	and	other	painful	disorders	in	the	dog	and	cat.	Management	of	chronic	pain	from	osteoarthritis	in	the	dog.	Ketoprofen	is	not	COX-2	selective	and	is	not	authorized	for	preoperative	administration	to	cats	and	dogs.			
COX-1	and	LOX	inhibition	
Mavacoxib	 2	mg/kg	orally.	Give	the	first	two	doses	14	days	apart	then	monthly	(not	to	exceed	6.5	months	of	therapy)	
For	the	treatment	of	pain	and	inflammation	associated	with	degenerative	joint	disease	in	dogs	at	least	12	months	old	in	cases	where	continuous	treatment	exceeding	one	month	is	indicated	
Preferential	inhibition	of	COX-2	mediated	PG	synthesis	
Meloxicam	 Dogs	-	0.2	mg/kg	injectable	or	oral	once,	followed	by	0.1	mg/kg	oral	suspension	once	daily	Cats	–	0.2	mg/kg	injectable	or	oral	once,	followed	by	0.05	mg/kg	oral	suspension	once	daily	
Control	of	acute	and	chronic	pain	of	musculoskeletal	disorders	and	inflammation	associated	with	OA	in	dogs.	Reduction	of	postoperative	pain	and	inflammation	following	orthopaedic	or	soft	tissue	surgery	
Preferential	inhibition	of	COX-2	
Paracetamol	+	codeine	 1	tablet	per	12	kg	bodyweight	three	times	daily	(treat	for	a	maximum	of	5	days)	
Control	of	mild	to	moderate	pain	 Mechanism	of	action	unknown	
Phenylbutazone	 2-20	mg/kg	orally	q.	8-12	hours	 Management	of	mild	to	moderate	pain	and	 COX-1	inhibitor	
inflammation	in	osteoarthritic	conditions.		Not	for	peri-operative	use.	Robenacoxib	 2	mg/kg	s.c.	once	daily	for	a	maximum	of	2	doses;		1–2	mg/kg	orally,	once	daily	(in	cats	for	up	to	6	days).		
Alleviation	of	inflammation	and	pain	in	both	acute	and	chronic	musculoskeletal	disorders,	and	the	reduction	of	postoperative	pain	and	inflammation	following	orthopaedic	and	soft	tissue	surgery	in	dogs.	Treatment	of	acute	pain	and	inflammation	in	cats.		
COX-2	selective	
Tolfenamic	acid	 Dogs	-	4	mg/kg	i.m.,	s.c.,	may	be	repeated	once	after	24h;	4	mg/kg	orally	for	3	days.		Oral	dosing	can	be	repeated	every	7	days	in	dogs		Cats	-	4	mg/kg	s.c.,	may	be	repeated	once	after	24h;	4	mg/kg	orally.	for	3	days.			
Alleviation	of	inflammation	and	pain	in	dogs	and	cats.	Also	used	in	the	management	of	chronic	locomotor	disease	in	dogs			
COX	inhibition,	direct	action	of	antagonism	on	PG	receptors	
COX	–	cyclo-oxygenase;	LOX	–	lipoxygenase;	OA	–	osteoarthritis;	PG	-	prostaglandin				 	
		Figure	1	–	Obesity	is	a	major	factor	in	osteoarthritis	and	weight	loss	remains	one	of	the	best	treatment	strategies	for	these	dogs		Figure	2	(a	and	b)	–	Passive	range	of	motion	exercises	such	as	joint	flexion	and	extension	can	easily	be	performed	at	home			Figure	3	(a	and	b)	-	Lateral	radiographs	of	the	tarsus	of	a	6-year-old,	Labrador	Retriever	with	a	chronic	calcaneal	tendon	injury	and	degenerative	joint	disease.	Pantarsal	arthrodesis	was	performed	to	stabilise	the	joint	and	manage	the	discomfort	associated	with	the	condition		Figure	4	(a	and	b)	-	Severe	hip	osteoarthritis	in	a	6-year-old,	German	Shepherd	Dog.	Femoral	head	and	neck	ostectomy	was	performed	to	relieve	clinical	signs	and	improve	limb	function	on	the	right.	The	dog	regained	good	limb	function	and	has	not	yet	required	further	surgery	on	the	contralateral	limb		Figure	5	(a	and	b)	-	Degenerative	change	in	the	hips	of	a	16-month-old	Labradoodle.	Total	hip	arthroplasty	was	performed	to	improve	this	dogs’	quality	of	life	due	to	severe	lameness	and	discomfort	during	hip	manipulation.	Significant	improvement	was	seen	after	surgery				 	
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